RBC Capital analyst Gregory Renza reiterated an Outperform rating and $32.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE